In summary, these findings demonstrate for the first time, the efficacy of a stable orally active vitamin E derivative (α-TEA) plus HER2/neu-specific antibody in treating established HER2/neu positive breast cancer and highlight the potential usefulness of α-TEA, a relatively non-toxic chemotherapeutic agent, for treating HER2/neu positive or negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.